467 related articles for article (PubMed ID: 38449875)
41. Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target.
Mousavi-Niri N; Naseroleslami M; Hadjati J
Hum Vaccin Immunother; 2019; 15(3):620-624. PubMed ID: 30633616
[TBL] [Abstract][Full Text] [Related]
42. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.
Yan Y; Huang L; Liu Y; Yi M; Chu Q; Jiao D; Wu K
J Hematol Oncol; 2022 Aug; 15(1):104. PubMed ID: 35948909
[TBL] [Abstract][Full Text] [Related]
43. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
Li C; Jiang P; Wei S; Xu X; Wang J
Mol Cancer; 2020 Jul; 19(1):116. PubMed ID: 32680511
[TBL] [Abstract][Full Text] [Related]
44. Foxp3, Regulatory T Cell, and Autoimmune Diseases.
Tao JH; Cheng M; Tang JP; Liu Q; Pan F; Li XP
Inflammation; 2017 Feb; 40(1):328-339. PubMed ID: 27882473
[TBL] [Abstract][Full Text] [Related]
45. Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment.
McRitchie BR; Akkaya B
Front Immunol; 2022; 13():940052. PubMed ID: 36248808
[TBL] [Abstract][Full Text] [Related]
46. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
47. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.
Chaudhary B; Abd Al Samid M; al-Ramadi BK; Elkord E
Expert Opin Biol Ther; 2014 Jul; 14(7):931-45. PubMed ID: 24661020
[TBL] [Abstract][Full Text] [Related]
49. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
50. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
51. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
[TBL] [Abstract][Full Text] [Related]
52. Lineage Reprogramming of Effector Regulatory T Cells in Cancer.
Dixon ML; Leavenworth JD; Leavenworth JW
Front Immunol; 2021; 12():717421. PubMed ID: 34394124
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer.
Fattori S; Roux H; Connen E; Robert L; Gorvel L; Le Roy A; Houacine J; Foussat A; Chretien AS; Olive D
Cancer Res; 2022 Nov; 82(21):3868-3879. PubMed ID: 36040356
[TBL] [Abstract][Full Text] [Related]
54. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
55. Regulatory T Cells in the Tumor Microenvironment.
Dadey RE; Workman CJ; Vignali DAA
Adv Exp Med Biol; 2020; 1273():105-134. PubMed ID: 33119878
[TBL] [Abstract][Full Text] [Related]
56. Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth.
Alfar R; Napoleon JV; Shahriar I; Finnell R; Walchle C; Johnson A; Low PS
Front Immunol; 2023; 14():1274199. PubMed ID: 37928524
[TBL] [Abstract][Full Text] [Related]
57. Targeting tumor-infiltrating tregs for improved antitumor responses.
Qin D; Zhang Y; Shu P; Lei Y; Li X; Wang Y
Front Immunol; 2024; 15():1325946. PubMed ID: 38500876
[TBL] [Abstract][Full Text] [Related]
58. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.
Sasidharan Nair V; Saleh R; Toor SM; Cyprian FS; Elkord E
Cancer Immunol Immunother; 2021 Aug; 70(8):2103-2121. PubMed ID: 33532902
[TBL] [Abstract][Full Text] [Related]
59. TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy.
Li L; Liu X; Sanders KL; Edwards JL; Ye J; Si F; Gao A; Huang L; Hsueh EC; Ford DA; Hoft DF; Peng G
Cell Metab; 2019 Jan; 29(1):103-123.e5. PubMed ID: 30344014
[TBL] [Abstract][Full Text] [Related]
60. Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape.
Su X; Sun T; Li M; Xia Y; Li M; Wang D; Lu F; Ye J; Ji C
J Transl Med; 2022 Aug; 20(1):378. PubMed ID: 35986288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
